Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291173 · ClinicalTrials.gov registry record · Phase 2
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 271
- Enrollment target
NCT01291173 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 271 participants.
The verdict
NCT01291173, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 271 participants
- Enrollment target
Study Summary
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
Interventions
- DRUG Placebo
- DRUG lisdexamfetamine dimesylate (SPD489)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2011-05-10 |
| Est. Completion | 2012-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01291173
The ClinicalTrials.gov registry entry for NCT01291173 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01291173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01291173 about?
NCT01291173 is a clinical study titled "Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder". To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
What is the current status of trial NCT01291173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 271 participants. The study started on 2011-05-10. Estimated completion is 2012-01-30.
What interventions are being tested in trial NCT01291173?
The interventions under investigation include: Placebo (DRUG), lisdexamfetamine dimesylate (SPD489) (DRUG).
Who is sponsoring clinical trial NCT01291173?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.